Condition: Heart Failure With Preserved Ejection Fraction · Sponsor: University of Pennsylvania
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
This description comes directly from the study's public registry record.
Melissa Fernando · 2672536141 · fernand@Pennmedicine.upenn.edu
Cassandra Demastus, CRNP · Cassandra.Demastus@Pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Pennsylvania Health System | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05138575